Selected research
Market Outlook & Growth Opportunities
Global Drugs for PNH Market Outlook and Growth Opportunities 2026
Market perspective
The global Drugs for PNH market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Drugs for PNH is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Drugs for PNH is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Drugs for PNH is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Drugs for PNH market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Drugs for PNH market include Alexion Pharmaceuticals, Amgen, Apellis Pharmaceuticals, Roche, Novartis and Samsung Bioepis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Drugs for PNH market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Drugs for PNH and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Drugs for PNH sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Drugs for PNH market size, projected growth trends, production technologies, key applications, and end-use industries.
Drugs for PNH Segment by Company
Alexion Pharmaceuticals
Amgen
Apellis Pharmaceuticals
Roche
Novartis
Samsung Bioepis
Drugs for PNH Segment by Type
Complement Inhibitors
Others
Drugs for PNH Segment by Application
Hospital
Clinic
Other
Drugs for PNH Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Drugs for PNH status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Drugs for PNH market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Drugs for PNH significant trends, drivers, influence factors in global and regions.
6. To analyze Drugs for PNH competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for PNH market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drugs for PNH and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for PNH.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Drugs for PNH market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs for PNH industry.
Chapter 3: Detailed analysis of Drugs for PNH manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Drugs for PNH in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Drugs for PNH in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Complement Inhibitors
- Others
Applications
- Hospital
- Clinic
- Other
Companies covered
- Alexion Pharmaceuticals
- Amgen
- Apellis Pharmaceuticals
- Roche
- Novartis
- Samsung Bioepis
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Drugs for PNH Sales Value (2021-2032)
- 1.2.2 Global Drugs for PNH Sales Volume (2021-2032)
- 1.2.3 Global Drugs for PNH Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Drugs for PNH Market Dynamics
- 2.1 Drugs for PNH Industry Trends
- 2.2 Drugs for PNH Industry Drivers
- 2.3 Drugs for PNH Industry Opportunities and Challenges
- 2.4 Drugs for PNH Industry Restraints
3 Drugs for PNH Market by Company
- 3.1 Global Drugs for PNH Company Revenue Ranking in 2025
- 3.2 Global Drugs for PNH Revenue by Company (2021-2026)
- 3.3 Global Drugs for PNH Sales Volume by Company (2021-2026)
- 3.4 Global Drugs for PNH Average Price by Company (2021-2026)
- 3.5 Global Drugs for PNH Company Ranking (2024-2026)
- 3.6 Global Drugs for PNH Company Manufacturing Base and Headquarters
- 3.7 Global Drugs for PNH Company Product Type and Application
- 3.8 Global Drugs for PNH Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Drugs for PNH Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Drugs for PNH Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Drugs for PNH Market by Type
- 4.1 Drugs for PNH Type Introduction
- 4.1.1 Complement Inhibitors
- 4.1.2 Others
- 4.2 Global Drugs for PNH Sales Volume by Type
- 4.2.1 Global Drugs for PNH Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Drugs for PNH Sales Volume by Type (2021-2032)
- 4.2.3 Global Drugs for PNH Sales Volume Share by Type (2021-2032)
- 4.3 Global Drugs for PNH Sales Value by Type
- 4.3.1 Global Drugs for PNH Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Drugs for PNH Sales Value by Type (2021-2032)
- 4.3.3 Global Drugs for PNH Sales Value Share by Type (2021-2032)
5 Drugs for PNH Market by Application
- 5.1 Drugs for PNH Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Other
- 5.2 Global Drugs for PNH Sales Volume by Application
- 5.2.1 Global Drugs for PNH Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Drugs for PNH Sales Volume by Application (2021-2032)
- 5.2.3 Global Drugs for PNH Sales Volume Share by Application (2021-2032)
- 5.3 Global Drugs for PNH Sales Value by Application
- 5.3.1 Global Drugs for PNH Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Drugs for PNH Sales Value by Application (2021-2032)
- 5.3.3 Global Drugs for PNH Sales Value Share by Application (2021-2032)
6 Drugs for PNH Regional Sales and Value Analysis
- 6.1 Global Drugs for PNH Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Drugs for PNH Sales by Region (2021-2032)
- 6.2.1 Global Drugs for PNH Sales by Region: 2021-2026
- 6.2.2 Global Drugs for PNH Sales by Region (2027-2032)
- 6.3 Global Drugs for PNH Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Drugs for PNH Sales Value by Region (2021-2032)
- 6.4.1 Global Drugs for PNH Sales Value by Region: 2021-2026
- 6.4.2 Global Drugs for PNH Sales Value by Region (2027-2032)
- 6.5 Global Drugs for PNH Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Drugs for PNH Sales Value (2021-2032)
- 6.6.2 North America Drugs for PNH Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Drugs for PNH Sales Value (2021-2032)
- 6.7.2 Europe Drugs for PNH Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Drugs for PNH Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Drugs for PNH Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Drugs for PNH Sales Value (2021-2032)
- 6.9.2 South America Drugs for PNH Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Drugs for PNH Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Drugs for PNH Sales Value Share by Country, 2025 VS 2032
7 Drugs for PNH Country-level Sales and Value Analysis
- 7.1 Global Drugs for PNH Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Drugs for PNH Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Drugs for PNH Sales by Country (2021-2032)
- 7.3.1 Global Drugs for PNH Sales by Country (2021-2026)
- 7.3.2 Global Drugs for PNH Sales by Country (2027-2032)
- 7.4 Global Drugs for PNH Sales Value by Country (2021-2032)
- 7.4.1 Global Drugs for PNH Sales Value by Country (2021-2026)
- 7.4.2 Global Drugs for PNH Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.9.2 France Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.16.2 China Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.19.2 India Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Drugs for PNH Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Drugs for PNH Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Drugs for PNH Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Drugs for PNH Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Alexion Pharmaceuticals
- 8.1.1 Alexion Pharmaceuticals Company Information
- 8.1.2 Alexion Pharmaceuticals Business Overview
- 8.1.3 Alexion Pharmaceuticals Drugs for PNH Sales, Value and Gross Margin (2021-2026)
- 8.1.4 Alexion Pharmaceuticals Drugs for PNH Product Portfolio
- 8.1.5 Alexion Pharmaceuticals Recent Developments
- 8.2 Amgen
- 8.2.1 Amgen Company Information
- 8.2.2 Amgen Business Overview
- 8.2.3 Amgen Drugs for PNH Sales, Value and Gross Margin (2021-2026)
- 8.2.4 Amgen Drugs for PNH Product Portfolio
- 8.2.5 Amgen Recent Developments
- 8.3 Apellis Pharmaceuticals
- 8.3.1 Apellis Pharmaceuticals Company Information
- 8.3.2 Apellis Pharmaceuticals Business Overview
- 8.3.3 Apellis Pharmaceuticals Drugs for PNH Sales, Value and Gross Margin (2021-2026)
- 8.3.4 Apellis Pharmaceuticals Drugs for PNH Product Portfolio
- 8.3.5 Apellis Pharmaceuticals Recent Developments
- 8.4 Roche
- 8.4.1 Roche Company Information
- 8.4.2 Roche Business Overview
- 8.4.3 Roche Drugs for PNH Sales, Value and Gross Margin (2021-2026)
- 8.4.4 Roche Drugs for PNH Product Portfolio
- 8.4.5 Roche Recent Developments
- 8.5 Novartis
- 8.5.1 Novartis Company Information
- 8.5.2 Novartis Business Overview
- 8.5.3 Novartis Drugs for PNH Sales, Value and Gross Margin (2021-2026)
- 8.5.4 Novartis Drugs for PNH Product Portfolio
- 8.5.5 Novartis Recent Developments
- 8.6 Samsung Bioepis
- 8.6.1 Samsung Bioepis Company Information
- 8.6.2 Samsung Bioepis Business Overview
- 8.6.3 Samsung Bioepis Drugs for PNH Sales, Value and Gross Margin (2021-2026)
- 8.6.4 Samsung Bioepis Drugs for PNH Product Portfolio
- 8.6.5 Samsung Bioepis Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Drugs for PNH Value Chain Analysis
- 9.1.1 Drugs for PNH Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Drugs for PNH Sales Mode & Process
- 9.2 Drugs for PNH Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Drugs for PNH Distributors
- 9.2.3 Drugs for PNH Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst